

August 29, 2007



Oculus Innovative Sciences to Present at Roth Capital Partners 2007 New York Conference

PETALUMA, Calif.--(BUSINESS WIRE)--

Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) announced today that the company will be presenting at the Roth Capital Partners 2007 Conference to be held September 5-6, 2007 at the Westin New York at Times Square. The company's president and chief executive officer, Hoji Alimi, is scheduled to present an overview of the company, its clinical programs and most recent quarter on Wednesday, September 5 at 12:00 p.m. (EDT) in room Majestic II, Track 1. For more information on this event please visit www.rothcp.com.

To access a live audio webcast of Mr. Alimi's presentation, please log on to Oculus Innovative Sciences' website at <http://ir.oculusis.com/events.cfm> approximately 15 minutes prior to the presentation in order to register and download any necessary software. The webcast will be available for one year at this website.

About Oculus

Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn(R) Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform is a solution of non-irritating, small molecule oxychlorine compounds with the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores. It has been commercialized outside of the U.S. for the treatment of infected wounds. It is currently under evaluation for the treatment of mildly infected diabetic ulcers under the brand name of Dermacyn(TM) in the U.S.

Oculus' principal operations are in Petaluma, California, and it conducts operations in Europe, Latin America and Japan through its wholly owned subsidiaries, Oculus Innovative Sciences Netherlands B.V., Oculus Technologies of Mexico, S.A. de C.V. and Oculus Japan K.K. Oculus' website is www.oculusis.com.

Source: Oculus Innovative Sciences, Inc.